

# INTERNATIONAL COOPERATION FOR INFECTIOUS DISEASES : A SURVEY

**Pr Patrice DEBRE**  
*Pitié-Salpêtrière Hospital,  
National Academy of Medicine*

**Laboratoire Immunité & Infection  
INSERM UMR-S 945  
Hôpitaux Universitaires  
La Pitié Salpêtrière - Charles Foix  
Paris, France**



# **The fight AGAINST HIV/AIDS TUBERCULOSIS AND MALARIA**

- Millennium Goals ( world leaders summit UN 2000, 193 Member States, 23 international organizations)
- 4 ) reducing children mortality rate
- 5) improving maternal health
- 6) combating HIV/AIDS and other diseases
- (1 eradicating extreme poverty and hunger)
- (2 developing global partnership for development

# THE FIGHT AGAINST infectious diseases

	Multilateral International	Multilateral Europe	Bilatéral France
Pandemics	+	+	+
Neglected diseases		+	
Emerging Diseases			+

## Global summary of the AIDS epidemic | 2011

<b>Number of people living with HIV</b>	<b>Total</b>	<b>34.2 million</b> [31.8 million–35.9 million]
	<b>Adults</b>	<b>30.7 million</b> [28.6 million–32.2 million]
	<b>Women</b>	<b>16.7 million</b> [15.7 million–17.8 million]
	<b>Children (&lt;15 years)</b>	<b>3.4 million</b> [3.1 million–3.9 million]

---


<b>People newly infected with HIV in 2011</b>	<b>Total</b>	<b>2.5 million</b> [2.2 million–2.8 million]
	<b>Adults</b>	<b>2.2 million</b> [2.0 million–2.4 million]
	<b>Children (&lt;15 years)</b>	<b>330 000</b> [280 000–380 000]

---


<b>AIDS deaths in 2011</b>	<b>Total</b>	<b>1.7 million</b> [1.6 million–1.9 million]
	<b>Adults</b>	<b>1.5 million</b> [1.3 million–1.7 million]
	<b>Children (&lt;15 years)</b>	<b>230 000</b> [200 000–270 000]



# Disparities in ART coverage between regions and populations



**Figure.** HIV/AIDS and malaria are highly endemic, and there is wide geographic overlap in sub-Saharan Africa. Among the most severely affected countries are Cameroon, Central African Republic, Malawi, Mozambique and Zambia where more than 90% of the population is exposed to malaria and HIV prevalence (among adults 15-49 years of age) is above 10%. Outside Africa, the two diseases overlap in certain at-risk groups in South-East Asia and South America, and in several Indian cities such as Mumbai.




**Distribution of HIV prevalence**

**Distribution of endemic malaria**



# The 22 High Burden Tuberculosis (TB) Countries (HBCs), 2011



**HBCs account for approximately 80% of all TB cases in the world**

SOURCE: Kaiser Family Foundation, [www.GlobalHealthFacts.org](http://www.GlobalHealthFacts.org), based on WHO, *Global Tuberculosis Control*, 2011.

# The fight against HIV/AIDS TUBERCULOSIS and MALARIA

- MULTILATERAL. FUNDING AGENCIES

- 
- 
- 

-Global Fund  
-UNITAID  
-EDCTP



- MULTILATERAL ADVOCACY

- 
- 

-RBM  
-UNAIDS  
-STOP TB



- OTHER BILATERALS

-PEPFAR, USAID  
-DFID(UK)  
-BMZ( Germany)  
JICA( Japan )



- PRIVATE

-BILL and Melinda GATES  
-WORLD BANK. -Industry



# THE GLOBAL FUND

- **A Swiss foundation ( secretariat in Geneva )**
- **A public - private partnership**
- **Began operations in 2002**
- **28.3 billions pledge**



Investissons dans notre avenir

**Le Fonds mondial**

De lutte contre le sida, la tuberculose et le paludisme

# THE GLOBAL FUND

- **Funding 22.9 billions**
- **1000 programs in 151 countries**
- **270 millions insecticide treated nets**
- **9.3 million people treated anti TB**
- **3.6 million treated ART**

# THE GLOBAL FUND

**International public funding**

**-HIV 20%**

**-tuberculosis 65%**

**-malaria 65%**



Investissons dans notre avenir

**Le Fonds mondial**

De lutte contre le sida, la tuberculose et le paludisme

# MULTILATERAL FUNDING AGENCIES :UNITAID

- Hosted by WHO
- Strategy



-to improve market impact

-to negotiate low prices

-to develop specifically dosed medications( pediatrics ,resistance)



European  
Commission

# European Developing Countries Clinical Trials Partnership (EDCTP)



200 M €

200 M €




E D C T P

- **Public-Public Partnership: Joint initiative between 16 Member States and European Commission, established under art. 185**
- **Independent legal entity (EEIG)**
- **Coordination of European national programmes for clinical trials in Africa for HIV/AIDS, malaria, TB**
- **EC contribution of 200 mill Euro + MS contribution of 200 mill Euro**
- **Launched in 2004, to be renewed 2014 (EDCTP-2)**



European Commission

# ... medical interventions, in particular



## Diseases:

**HIV/AIDS, TB, Malaria, (EDCTP2: NIDs)**

## Interventions:

**Drugs, Vaccines, Microbicides, Diagnostics,**  
(EDCTP2: health systems research, health delivery research)





# Achievements I

## Capacity development for ethically sound and scientifically robust clinical trials

- **156 institutions** in **29 African countries** receiving 75% of EDCTP grants (42 European public institutions in the 14 European partner countries)
- **More than 1100 African researchers** involved and **351** directly supported through EDCTP grants (incl. 150 training grants and fellowships)
- **4 African Networks of Excellence for clinical trials** have been established in the 4 main sub-Saharan regions
- National **regulatory authorities** and **ethics review capacities** have been strengthened in many African countries (75 EDCTP-funded activities)
- **Pan-African Clinical Trials Registry (PACTR)** was established as an African initiative funded by EDCTP (today WHO Primary Registry), <http://www.pactr.org/>





## Achievements II

### Identification of candidate products and support to clinical trials (mainly Phase 1 - 3)

- **57 EDCTP-funded clinical trials** (48 still ongoing)
  - 27 are on **HIV/AIDS** (€ 118 million)
  - 18 on **tuberculosis** (€ 110 million)
  - 12 on **malaria** (€ 76 million)
- **More than 100'000 patients involved:** in particular CTs on infants (8), children/adolescents (17), and pregnant or lactating women (5)
- **Predominantly African leadership:** 52% of clinical trials (70% with African PI for all EDCTP grants)




# FRENCH CONTRIBUTION FOR HEALTH



- 2000-2011 more than doubled
- 2007-2009 2590 millions dollars (multi and bi)
- 2011-2016 mother and child ( muskoka):  
500 millions E
- -20%increase for Global Fund:360 millions Euros/  
year 2011-2013
- -pluriannual funding for UNITAID:110millions  
Euros/year 2011-2013

# **FRENCH STRATEGY FOR HEALTH (INTERNATIONAL )**



## **Multilateral**

**-to support health systems and clinical research  
(pandemics)**

**-to set up programs relating health and environment  
(emerging diseases)**

**-to fight for human rights**

**-to develop relationship with Francophone countries ( Africa)**

## **Bilateral**

**-to coordinate activities within research institutes (AVIESAN)**

# The French National Alliance for Life and Health Sciences (Aviesan)


aviesan  
alliance nationale  
pour les sciences de la vie et de la santé



April 9, 2009

# Aviesan

## 10 multi-organization thematic institutes (Itmos)



## **Some Remarks for Improvement**

- **A continuum between health systems strengthening(exple the Global funds) and clinical research (exple EDCTP)**
- **Some overlapping phase IV are supported both by UNITAID and EDCTP**
- **Different bilateral operators (PEPFAR , USAID, CHAI,DIFID, different French (5%) organizations public and private (NGO)**
- **South is diverse (no real analysis of demand nor coperations between operators in implementing countries)**

## **Some Remarks for Improvement**

- **No shared strategy between the multilaterals, between specific funding agencies and advocacy agencies and relationship with others WHO, UNICEF.**
- **No strategy to link health strengthening and research nor to valorize or coordinate research.**
- **Different funding between multilateral (cash and or kind)**



## **Some Remarks for Improvement**

- **No clear link between bilateral and multilateral but recent initiatives (French 5% although limited to the Global funds, EDCTP joint programming)**
- **No coordination of efforts (French and others) to link operations inside countries.**
- **No analysis and comparison between needs and offers**

## **Some Proposals for Improvement**

- **At global level: Create Adhoc interactions between agencies (informations and shared strategy for complementary fundings, approach with third parties / GATES etc...**
- **From French perspectives. Three levels : 1) high level council for analysis and strategy 2) Alliance between institutional operators (ie IRD, Pasteur, INSERM, hospitals) and funding agencies (5% MAEE, ANRS). 3) Coordinated actions between teams supporting Health and/or research**